A recent increase in the literature regarding the evidence base for clozapine has made it
increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we …

Introduction Antipsychotic medications are mainstays in the treatment of schizophrenia and
a range of other psychotic disorders. Sources of data Recent meta-analyses of antipsychotic …

The current and long-term health of 14.4 million children and adolescents is affected by
obesity, 1, 2 making it one of the most common pediatric chronic diseases. 3–5 Long …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Abstract Cosponsoring Associations: The European Society of Endocrinology and the
Pediatric Endocrine Society. This guideline was funded by the Endocrine Society. Objective …

Objectives: This guideline provides recommendations for the clinical management of
schizophrenia and related disorders for health professionals working in Australia and New …

People with severe mental illness have a considerably shorter lifespan than the general
population. This excess mortality is mainly due to physical illness. Next to mental illness …

Antipsychotic-induced weight gain is a major management problem for clinicians. It has
been shown that weight gain and obesity lead to increased cardiovascular and …

Background Severe mental illness (SMI; schizophrenia, bipolar disorders (BDs), and other
nonorganic psychoses) is associated with increased risk of cardiovascular disease (CVD) …

Introduction: Antipsychotic-induced weight-gain (AIWG) is a very important, yet often
neglected side-effect in the treatment with first and second generation antipsychotics. AIWG …